Niranjana D Amin Selected Research

Cyclin-Dependent Kinase 5

1/2018	Phosphorylation of the Transient Receptor Potential Ankyrin 1 by Cyclin-dependent Kinase 5 affects Chemo-nociception.
1/2017	TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.
1/2015	Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
12/2013	Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia.
1/2013	A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.
5/2010	Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor.
7/2007	Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niranjana D Amin Research Topics

Disease

9	Alzheimer Disease (Alzheimer's Disease) 09/2019 - 09/2008
9	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2015 - 07/2007
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2019 - 09/2008
3	Amyloid Plaque 01/2017 - 01/2013
3	Parkinson Disease (Parkinson's Disease) 12/2015 - 12/2009
2	Neuroinflammatory Diseases 12/2015 - 01/2014
1	Inflammation (Inflammations) 01/2018
1	Wilms Tumor (Wilm's Tumor) 01/2016
1	Kidney Diseases (Kidney Disease) 01/2016
1	Type 2 Diabetes Mellitus (MODY) 01/2014
1	Facial Pain (Myofacial Pain) 12/2013
1	Hyperalgesia 12/2013
1	Lung Neoplasms (Lung Cancer) 08/2012
1	Carcinoid Tumor (Carcinoid) 08/2012
1	Motor Neuron Disease (Primary Lateral Sclerosis) 12/2009

Drug/Important Bio-Agent (IBA)

9	Phosphotransferases (Kinase)IBA 09/2019 - 08/2012
7	Peptides (Polypeptides)IBA 10/2019 - 10/2010
7	Cyclin-Dependent Kinase 5IBA 01/2018 - 07/2007
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 12/2009
2	TFP5 peptideIBA 12/2015 - 01/2014
2	Cytoskeletal ProteinsIBA 12/2009 - 09/2008
1	EnzymesIBA 09/2019
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 01/2017
1	Caspase 3 (Caspase-3)IBA 01/2016
1	Amino Acids FDA Link 01/2016
1	Dopamine (Intropin)FDA LinkGeneric 12/2015
1	Neuroprotective AgentsIBA 12/2015
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2015
1	Protein Kinases (Protein Kinase)IBA 01/2015
1	Interleukin-6 (Interleukin 6)IBA 01/2014
1	CytokinesIBA 01/2014
1	Analgesics (Analgesic Drugs)IBA 12/2013
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 07/2013
1	RoscovitineIBA 08/2012
1	Small Interfering RNA (siRNA)IBA 08/2012
1	LigandsIBA 07/2007
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 07/2007

Therapy/Procedure

2	Therapeutics 01/2014 - 01/2013